What is Faeth Therapeutics?
Faeth Therapeutics operates at the vanguard of clinical-stage biotechnology, specializing in metabolism-based cancer therapies. The company utilizes a sophisticated AI-driven computational biology engine to identify and exploit metabolic vulnerabilities within tumors. By integrating precision nutrition with targeted therapeutic interventions, Faeth Therapeutics aims to fundamentally improve patient outcomes and redefine standard oncology treatment protocols. Their market position is defined by a multidisciplinary approach that bridges the gap between nutritional science and molecular oncology, creating a distinct competitive advantage in the high-stakes biotech landscape.
How much funding has Faeth Therapeutics raised?
Faeth Therapeutics has raised a total of $92M across 3 funding rounds:
Angel/Seed
$20M
Series A
$47M
Other Financing Round
$25M
Angel/Seed (2022): $20M with participation from S2G Ventures, Khosla Ventures, and Future Ventures
Series A (2022): $47M led by Future Ventures, Khosla Ventures, and S2G Ventures
Other Financing Round (2025): $25M supported by Future Technologies, S2G Ventures, Khosla Ventures, and Digitalis Ventures
Key Investors in Faeth Therapeutics
Khosla Ventures
A prominent venture firm providing strategic advice and capital to entrepreneurs working on breakthrough technologies across health, AI, and sustainable energy sectors.
Future Ventures
A firm focused on mission-driven founders and frontier technologies, known for backing disruptive innovations that have the potential to reinvent global industries.
S2G Ventures
A multi-stage fund specializing in the food and agriculture supply chain, investing in companies that align innovation with the shifting demands for health and sustainability.
What's next for Faeth Therapeutics?
With the infusion of this latest capital, Faeth Therapeutics is well-positioned to scale its innovative oncology programs and advance its pipeline through critical clinical trial phases. The strategic focus will likely center on expanding the reach of its metabolic therapy platform, potentially entering new therapeutic areas where metabolic intervention can provide superior efficacy. As the company matures, the emphasis will shift toward validating its clinical data and establishing long-term partnerships that can facilitate the commercialization of its precision medicine solutions. Investors remain focused on the company's ability to translate computational insights into tangible, life-saving medical breakthroughs.
See full Faeth Therapeutics company page
